Oncogenic potential of yin yang 1 mediated through control of imprinted genes.

The transcription factor Yin Yang (YY) 1 is one of the most evolutionarily well-conserved DNA binding proteins that is ubiquitously expressed among different tissue types. YY1 functions as a critical regulator for a diverse set of genes, making its role in the cancerous environment elusive. Recent studies have demonstrated that clusters of YY1 binding sites are overrepresented in imprinted gene loci. These clustered binding sites may function as a molecular rheostat with respect to YY1 protein levels. YY1 levels were documented to be altered in various tumor tissues in conjunction with the transcriptional levels of the imprinted genes it regulates. This review highlights the unexplored mechanism through which fluctuations in YY1 protein levels alter the transcriptional status of imprinted genes containing clustered YY1 binding sites, which potentially could affect cancer development and/or progression.

[1]  G. Rosner,et al.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy , 2011, Cancer.

[2]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[3]  Jeannie T. Lee,et al.  YY1 Tethers Xist RNA to the Inactive X Nucleation Center , 2011, Cell.

[4]  M. Esteller.  Epigenetic changes in cancer , 2011, F1000 biology reports.

[5]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.

[6]  N. Coleman,et al.  Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells , 2011, Journal of Neuro-Oncology.

[7]  Qizhi Yao,et al.  Expression and Function of a Large Non-coding RNA Gene XIST in Human Cancer , 2011, World Journal of Surgery.

[8]  P. Altmeyer,et al.  GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma , 2010, European journal of medical research.

[9]  R. Feil,et al.  Genomic imprinting and human disease. , 2010, Essays in biochemistry.

[10]  A. Lania,et al.  GNAS imprinting and pituitary tumors , 2010, Molecular and Cellular Endocrinology.

[11]  K. Nishio,et al.  Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. , 2010, Gynecologic oncology.

[12]  D. Spandidos,et al.  Yin Yang 1 expression in human tumors , 2010, Cell cycle.

[13]  G. Dranitsaris,et al.  CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. , 2010, Leukemia research.

[14]  A. Wutz,et al.  ConteXt of change—X inactivation and disease , 2010, EMBO molecular medicine.

[15]  M. Atchison,et al.  PcG recruitment by the YY1 REPO domain can be mediated by Yaf2 , 2009, Journal of cellular biochemistry.

[16]  E. Maher,et al.  Genomic imprinting syndromes and cancer. , 2010, Advances in genetics.

[17]  M. Bartolomei.  Genomic imprinting: employing and avoiding epigenetic processes. , 2009, Genes & development.

[18]  Joomyeong Kim,et al.  YY1 is autoregulated through its own DNA-binding sites , 2009, BMC Molecular Biology.

[19]  Joomyeong Kim,et al.  YY1's role in DNA methylation of Peg3 and Xist , 2009, Nucleic acids research.

[20]  Giancarlo Castellano,et al.  The involvement of the transcription factor Yin Yang 1 in cancer development and progression , 2009, Cell cycle.

[21]  M. Oshimura,et al.  Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[22]  Joomyeong Kim,et al.  YY1's longer DNA-binding motifs. , 2009, Genomics.

[23]  Manuela Gariboldi,et al.  Misbehaviour of XIST RNA in Breast Cancer Cells , 2008, PloS one.

[24]  H. Hsu,et al.  Epigenetic Silencing of CCAAT/Enhancer-binding Protein δ Activity by YY1/Polycomb Group/DNA Methyltransferase Complex* , 2008, Journal of Biological Chemistry.

[25]  Joomyeong Kim.  Multiple YY1 and CTCF binding sites in imprinting control regions , 2008, Epigenetics.

[26]  Zhen Lu,et al.  Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.

[27]  Jeong Do Kim,et al.  In vivo YY1 knockdown effects on genomic imprinting. , 2008, Human molecular genetics.

[28]  M. Oshimura,et al.  Changes in expression of imprinted genes following treatment of human cancer cell lines with non-mutagenic or mutagenic carcinogens. , 2008, International journal of oncology.

[29]  Q. Liu,et al.  Prostaglandin F2alpha suppresses rat steroidogenic acute regulatory protein expression via induction of Yin Yang 1 protein and recruitment of histone deacetylase 1 protein. , 2007, Endocrinology.

[30]  K. Calame,et al.  YY1 helps to bring loose ends together. , 2007, Genes & development.

[31]  Jun Lu,et al.  HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. , 2007, Immunology letters.

[32]  L. Stubbs,et al.  YY1 as a controlling factor for the Peg3 and Gnas imprinted domains. , 2007, Genomics.

[33]  C. Napoli,et al.  Cooperation between Myc and YY1 provides novel silencing transcriptional targets of α3β1-integrin in tumour cells , 2007, Oncogene.

[34]  M. Atchison,et al.  Polycomb recruitment to DNA in vivo by the YY1 REPO domain , 2006, Proceedings of the National Academy of Sciences.

[35]  I. Ovcharenko,et al.  Identification of clustered YY1 binding sites in imprinting control regions. , 2006, Genome research.

[36]  Yang Shi,et al.  Essential Dosage-Dependent Functions of the Transcription Factor Yin Yang 1 in Late Embryonic Development and Cell Cycle Progression , 2006, Molecular and Cellular Biology.

[37]  Andrey Korshunov,et al.  Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH) , 2006, Acta Neuropathologica.

[38]  L. Stubbs,et al.  Rapid evolution of a recently retroposed transcription factor YY2 in mammalian genomes. , 2006, Genomics.

[39]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[40]  Stéphane Boissinot,et al.  Molecular evolution and tempo of amplification of human LINE-1 retrotransposons since the origin of primates. , 2005, Genome research.

[41]  E. Davidson.  Genomic Regulatory Systems: Development and Evolution , 2005 .

[42]  David I. Smith,et al.  Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. , 2005, Gynecologic oncology.

[43]  D. J. Driscoll,et al.  Characterization of cis- and trans-acting elements in the imprinted human SNURF-SNRPN locus , 2005, Nucleic acids research.

[44]  N. Kuldell,et al.  Zinc Finger Proteins: From Atomic Contact to Cellular Function , 2010 .

[45]  M. Bucan,et al.  Promoter features related to tissue specificity as measured by Shannon entropy , 2005, Genome Biology.

[46]  V. Babich,et al.  Clusters of regulatory signals for RNA polymerase II transcription associated with Alu family repeats and CpG islands in human promoters. , 2004, Genomics.

[47]  S. H. Kim,et al.  The Drosophila pleiohomeotic mutation enhances the Polycomblike and Polycomb mutant phenotypes during embryogenesis and in the adult. , 2003, The International journal of developmental biology.

[48]  H. Davies,et al.  Myeloid leukemia in Prader-Willi syndrome. , 2003, Jornal de Pediatria.

[49]  N. Gostling,et al.  From DNA to Diversity: Molecular Genetics and the Evolution of Animal Design , 2002, Heredity.

[50]  K. Bussey,et al.  SNRPN methylation patterns in germ cell tumors as a reflection of primordial germ cell development , 2001, Genes, chromosomes & cancer.

[51]  H. Yoshioka,et al.  Epigenetic silencing of PEG3 gene expression in human glioma cell lines * , 2001, Molecular carcinogenesis.

[52]  S Kobayashi,et al.  Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[53]  Yang Shi,et al.  The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 , 2000, Journal of Virology.

[54]  E. Seto,et al.  Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? , 1999, Gene.

[55]  C. Azuma,et al.  Loss of H19 imprinting and up-regulation of H19 and SNRPN in a case with malignant mixed Müllerian tumor of the uterus. , 1997, Human pathology.

[56]  M. Goodman,et al.  High affinity YY1 binding motifs: identification of two core types (ACAT and CCAT) and distribution of potential binding sites within the human beta globin cluster. , 1995, Nucleic acids research.

[57]  E. Jennings,et al.  DNA binding sites for the transcriptional activator/repressor YY1. , 1995, Nucleic acids research.

[58]  A. Feinberg,et al.  Parental Imprinting of Human Chromosome Region 11p15.3-pter Involved in the Beckwith-Wiedemann Syndrome and Various Human Neoplasia , 1994, European journal of human genetics : EJHG.

[59]  M. Atchison,et al.  Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3' enhancer and the immunoglobulin heavy-chain mu E1 site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Perry,et al.  Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc finger protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Yang Shi,et al.  Transcriptional repression by YY1, a human GLI-Krüippel-related protein, and relief of repression by adenovirus E1A protein , 1991, Cell.

[62]  C. Sapienza,et al.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. , 1989, Proceedings of the National Academy of Sciences of the United States of America.